From wiki-pain
Revision as of 07:24, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.52
First Reported 1979
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 7
Total Number 8
Disease Relevance 3.26
Pain Relevance 1.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Pde2a) signal transduction (Pde2a) Golgi apparatus (Pde2a)
endoplasmic reticulum (Pde2a) plasma membrane (Pde2a) nucleus (Pde2a)
Anatomy Link Frequency
nerve 1
Pde2a (Rattus norvegicus)
Pain Link Frequency Relevance Heat
depression 16 90.20 High High
Potency 1 89.20 High High
long-term potentiation 106 88.12 High High
gABA 1 86.28 High High
Glutamate 8 85.88 High High
opiate 1 85.48 High High
Clonidine 4 85.28 High High
agonist 4 84.88 Quite High
withdrawal 2 84.44 Quite High
headache 4 84.24 Quite High
Disease Link Frequency Relevance Heat
Hypoxia 6 99.92 Very High Very High Very High
Hypothermia 5 98.44 Very High Very High Very High
Cognitive Disorder 188 97.84 Very High Very High Very High
Opiate Addiction 3 93.04 High High
Depression 16 90.20 High High
Increased Venous Pressure Under Development 5 89.08 High High
Coronary Heart Disease 20 84.88 Quite High
Headache 4 84.24 Quite High
Vomiting 8 67.48 Quite High
Nociception 2 67.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
There was no correlation with potencies in inhibiting cyclic GMP phosphodiesterase.
Negative_regulation (inhibiting) of cyclic GMP phosphodiesterase
1) Confidence 0.52 Published 1979 Journal Eur. J. Pharmacol. Section Abstract Doc Link 217699 Disease Relevance 0.26 Pain Relevance 0.37
We studied 8-methoxy-IBMX as a selective PDE1 inhibitor, erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) and BAY 60-7550 as selective PDE2 inhibitors, sildenafil as a selective PDE5 inhibitor, dipyridamole as a mixed type PDE5 and PDE10 inhibitor, rolipram as a PDE4 inhibitor, and SCH 81566 as a selective PDE9 inhibitor. cGMP-IR structures (nerve fibers, axons, and terminals) were characterized using the following neurochemical markers: vesicular transporter molecules for acetylcholine, GABA, and glutamate (type 1 and type 2), parvalbumin, glutamate transporter molecule EAAT3, synaptophysin, substance P, calcitonin gene-related peptide, and isolectin B4.
Negative_regulation (inhibitors) of PDE2 in nerve associated with glutamate, gaba, calcitonin gene-related peptide and substance p
2) Confidence 0.36 Published 2006 Journal J. Chem. Neuroanat. Section Abstract Doc Link 16621445 Disease Relevance 0.07 Pain Relevance 0.36
Inhibitions of cyclic GMP phosphodiesterase and of superoxide production by hypoxia do not seem to participate in the action of hypothermia.
Negative_regulation (Inhibitions) of cyclic GMP phosphodiesterase associated with hypothermia and hypoxia
3) Confidence 0.28 Published 2003 Journal J. Pharmacol. Sci. Section Abstract Doc Link 12832836 Disease Relevance 1.14 Pain Relevance 0.07
It has been shown that inhibitors of PDE2, PDE4, PDE5, PDE9, and PDE10 improve a wide range of cognitive processes, including information processing, attention, learning, memory, executive functioning, and response inhibition, in various behavioral models within different species.
Negative_regulation (inhibitors) of PDE2 associated with cognitive disorder
4) Confidence 0.24 Published 2008 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2704616 Disease Relevance 0.87 Pain Relevance 0.18
Indomethacin reversed alpha(2) inhibition of CPT-cAMP-stimulated P(f), J(lb), and P(u), and subsequent addition of PGE(2) reduced transport in each case.
Negative_regulation (inhibition) of CPT-cAMP-stimulated
5) Confidence 0.12 Published 2000 Journal Am. J. Physiol. Renal Physiol. Section Abstract Doc Link 10919849 Disease Relevance 0 Pain Relevance 0.16
Conversely, reducing cGMP level e.g. by NOS inhibition, enhances ?
Negative_regulation (reducing) of cGMP
6) Confidence 0.09 Published 2005 Journal BMC Pharmacol Section Body Doc Link PMC1131906 Disease Relevance 0.40 Pain Relevance 0.03
PDE2, PDE4, and PDE9 inhibition improved both STM and LTM (see Tables 3, 4, and 6).
Negative_regulation (inhibition) of PDE2
7) Confidence 0.08 Published 2008 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2704616 Disease Relevance 0.51 Pain Relevance 0.42
CGS19281A, a phenylethanolamine N-methyltransferase (PNMT) inhibitor, is reported not to inhibit alpha-2-adrenoceptor activity, in vitro.
Negative_regulation (inhibitor) of CGS19281A
8) Confidence 0.05 Published 1996 Journal Neuropsychobiology Section Abstract Doc Link 8904737 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools